Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production

1. A method of treating or ameliorating adrenocortical cancer comprising co-administering to said patient a therapeutically effective amount of two or more agents selected from

1) an agent capable of inhibiting cholesterol efflux related to ABCA1 and/or ABCG1;

2) an agent capable of inhibiting MDR1 related cortisol secretion and/or MDR1 P-glycoprotein multiple drug transporter activity; and

3) an agent capable of inhibiting mitochondrial activity, and

further comprising administering to said patient one or more anticancer agents, wherein said anticancer agent is a chemotherapeutic agent and/or radiation therapy.

2. The method of claim 1 ,

wherein the agent capable of inhibiting cholesterol efflux related to ABCA1 and/or ABCG1 is selected from Valspodar, Glyburide, Cyclosporine A,

wherein the agent capable of inhibiting MDR1 related cortisol secretion and/or MDR1 P-glycoprotein multiple drug transporter activity is selected from Tariquidar, MK-571, Niguldipine hydrochloride, Matairesinol, Reversin 121 (C 34 H 47 N 3 O 9 ), Elacridar, Pyrimethamine (C 12 H 13 ClN 4 ), Pyrimethamine Biotin (C 27 H 39 N 7 O 3 S), Pyrimethamine-d3 (C 12 H 10 D 3 ClN 4 ), 8-isopentenylnaringenin, JS-2190 (Boc-Glu(OBzl)-N,N′-dicyclohexylurea, C 30 H 45 N 3 O 6 ), P-Glycoprotein Inhibitor C-4 (C 23 H 18 ClNO 4 ), PGP-4008, Sipholenol A, Reversan, CP 100356 hydrochloride, PSC 833, Zosuquidar trihydrochloride, and Vismodegib,

wherein the agent capable of inhibiting mitochondrial activity is selected from rhodamine-123, MKT-077, decoquinate, isoniazid, suramin, erythrosine, toltrazuril, enilconazole, and metformin.

3. The method of claim 1 , wherein said patient is a human patient.